Report 39: Despite Incomplete Safety Trials, the Food and Drug Administration (FDA) Grants Full Approval to Pfizer-BioNTech’s COMIRNATY® for Adolescents 12-15 Years of Age
Without a completed safety study or expert committee review, the FDA issued a supplemental Biologics License Application (“sBLA”) approval letter granting full FDA approval to Pfizer-BioNTech’s COMIRNATY® COVID-19 mRNA vaccine for use in children ages 12-15. This was done even though safety study completion, on which approval should be based, …
Report 43: Twenty-Two Cases of Rare Myocarditis by February 2021, Yet Pfizer Said No “New Safety Issues.” FDA Waits Until June 25, 2021, to Include Myocarditis Risk in Fact Sheets.
As initially reported by Chris Flowers, M.D., on DailyClout.io in April 2022, myocarditis – inflammation of the heart muscle (a.k.a., myocardium) that can reduce the heart’s ability to pump blood as well as cause chest pain, shortness of breath, and rapid or irregular heart rhythms (a.k.a., arrhythmias) [https://www.mayoclinic.org/diseases-conditions/myocarditis/symptoms-causes/syc-20352539] – …
Report 37: Pfizer, FDA, CDC Hid Proven Harms to Male Sperm Quality, Testes Function, from mRNA Vaccine Ingredients
When the COVID-19 vaccine rollout to the public began in late 2020, medical professionals, public health agencies, and government spokespeople all assured the American public that the novel mRNA vaccines did not cause negative systematic effects to human bodies. They promised the public, many of whom were skeptical about the …
Report 03: Phase 1 /2 Study of COVID-19 RNA Vaccine BNT162b1 in Adults: Key Processes Missing.
Mulligan, Lyke et al. Nature Published online August 12, 2020. Cite this article as: Mulligan, M. J. et al. Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults. Nature https://doi.org/10.1038/s41586-020-2639-4 (2020). P1 p2: The authors’ put forth the argument that mRNA in BNT162b1 (Note this series used BNT162b1 …